Galapagos Genomics NV And ASINEX Ltd. Announce Collaboration In Bone And Joint Diseases 
10/19/2005 5:10:15 PM

Mechelen, Belgium & Moscow, Russia, 12 May 2005 - Galapagos NV, a genomics-based drug discovery company and ASINEX Ltd, a worldwide leader in lead generation and optimization announce that they have initiated an integrated drug discovery collaboration in bone and joint diseases. The collaboration will result in a set of optimized leads for Galapagos' validated bone and joint disease drug targets. Financial details have not been disclosed.